For HCPs
Actor portrayals.
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
Gillmore JD, Judge DP, Cappelli F, et al. NEJM. 2024.
Results from ATTRibute-CM, a phase 3, double-blind, placebo-controlled study that evaluated the efficacy and safety of Attruby in patients with ATTR-CM.
External LinkLong-Term Efficacy and Safety of Acoramidis in ATTR-CM
Initial Report From the Open-Label Extension of the ATTRibute-CM Trial (Through 42 Months)
Judge DP, Gillmore JD, Alexander KM, et al. Circulation. 2025.
Results from an ongoing open-label extension study that was conducted to evaluate the long-term efficacy and safety of Attruby after 42 months of treatment.
External LinkEfficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
Judge DP, Alexander KM, Cappelli F, et al. J Am Coll Cardiol. 2025.
This publication reports prespecified secondary and post hoc analyses from the ATTRibute-CM study to further characterize the efficacy of acoramidis on the clinical outcomes of ACM and CVH.
External LinkLong-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy
Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial (Through 54 Months)
Soman P, Cuddy SM, Gilmore JD, et al. JAMA Cardiol. 2026.
Results from an ongoing open-label extension study that was conducted to evaluate the long-term efficacy and safety of Attruby after 54 months of treatment.
External LinkATTR-CM: Then and Now
Learn more about recent developments in disease state awareness and diagnostic approaches in ATTR-CM.
DownloadAdvances in ATTR-CM Imaging
Learn more about cardiac imaging, a reliable, noninvasive, and relatively inexpensive method that can be used to help diagnose and monitor ATTR-CM.
DownloadUnveiling ATTR-CM Among Patients with Common Cardiac Conditions
Learn more about signs and symptoms of ATTR-CM, and how to recognize these clues to make a diagnosis.
DownloadAdditional Information on Variant ATTR-CM
Learn more about variant ATTR-CM, who is primarily affected by this subtype, and how to identify it.
DownloadAttruby in Patients With Variant ATTR-CM
Learn more about the efficacy and safety of Attruby (acoramidis) in patients with variant ATTR-CM.
Download
Attruby Mechanism of Action Explained
Watch on YouTube
Common Lab Findings in Patients with ATTR-CM
Watch on YouTube
Stabilization of the TTR tetramer
Watch on YouTubeACM=all-cause mortality; ATTR-CM=transthyretin amyloid cardiomyopathy; CVH=cardiovascular hospitalization; TTR=transthyretin.
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.
Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.
Use in Specific Populations
Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.
Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Please see Full Prescribing Information including Patient Information.